Carolina De Ciuceis1, Claudia Agabiti-Rosei1, Claudia Rossini1, Stefano Caletti1, Maria Antonietta Coschignano1, Giulia Ferrari-Toninelli2, Giorgio Ragni3, Carlo Cappelli1, Bruno Cerudelli3, Paolo Airò4, Mirko Scarsi4, Angela Tincani4, Enzo Porteri1, Damiano Rizzoni5,6. 1. Clinica Medica, Department of Clinical and Experimental Sciences, University of Brescia, c/o 2ª Medicina, Spedali Civili, 25100, Brescia, Italy. 2. Division of Medicine, Istituto Clinico Città di Brescia, Brescia, Italy. 3. Division of Medicine, Spedali Civili di Brescia, Gardone Val Trompia, Italy. 4. Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy. 5. Clinica Medica, Department of Clinical and Experimental Sciences, University of Brescia, c/o 2ª Medicina, Spedali Civili, 25100, Brescia, Italy. damiano.rizzoni@unibs.it. 6. Division of Medicine, Istituto Clinico Città di Brescia, Brescia, Italy. damiano.rizzoni@unibs.it.
Abstract
INTRODUCTION: Glucagon-like peptide 1-receptor agonists (incretin mimetics) and dipeptidyl peptidase-4 inhibitors (incretin enhancers) have been recently introduced in the treatment of diabetes mellitus. In particular, incretin mimetics seems to have ancillary antioxidant/antinflammatory properties that might be involved in endothelial protection. AIM: To investigate the effect of incretin mimetic therapy (liraglutide, exenatide) given to 11 patients with type 2 diabetes mellitus, on circulating endothelial progenitor cells (EPCs) (bone marrow-derived cells possibly participating in neovascularization and endothelial protection and repair) and capillary density. METHODS: Four diabetic patients were treated with exenatide (5 μg twice daily for 4 weeks and then 10 μg twice daily for 3 weeks) and 7 with liraglutide (0.6 mg per day for 1 week and then 1.2 mg per day for 3 weeks). Peripheral venous blood samples were obtained before treatment (basal) and after 4 week in patients treated with liraglutide, and after 4 and 7 weeks in patients treated with exenatide, since drug titration is usually longer. EPCs were evaluated by flow cytometry as CD34+/KDR+ cells. Capillary density was evaluated by videomicroscopy, before and after venous congestion, in the dorsum of the 4th finger. RESULTS: Patients treated with liraglutide (6 males 1 female, age 54 ± 12 years) showed a decrease in body mass index and blood pressure during treatment, while patients treated with exenatide (3 males 1 female, age 57 ± 6 years) did not show any relevant change. EPCs were significantly increased after treatment with exenatide, but not after treatment with liraglutide. Capillary density was slightly increased only after 4 weeks of treatment with exenatide, however the increase was no longer present at the final evaluation. CONCLUSIONS: Treatment with exenatide, but not with liraglutide, was able to increase the number of circulating EPCs, possibly through an antioxidative/antiinflammatory effect.
INTRODUCTION: Glucagon-like peptide 1-receptor agonists (incretin mimetics) and dipeptidyl peptidase-4 inhibitors (incretin enhancers) have been recently introduced in the treatment of diabetes mellitus. In particular, incretin mimetics seems to have ancillary antioxidant/antinflammatory properties that might be involved in endothelial protection. AIM: To investigate the effect of incretin mimetic therapy (liraglutide, exenatide) given to 11 patients with type 2 diabetes mellitus, on circulating endothelial progenitor cells (EPCs) (bone marrow-derived cells possibly participating in neovascularization and endothelial protection and repair) and capillary density. METHODS: Four diabeticpatients were treated with exenatide (5 μg twice daily for 4 weeks and then 10 μg twice daily for 3 weeks) and 7 with liraglutide (0.6 mg per day for 1 week and then 1.2 mg per day for 3 weeks). Peripheral venous blood samples were obtained before treatment (basal) and after 4 week in patients treated with liraglutide, and after 4 and 7 weeks in patients treated with exenatide, since drug titration is usually longer. EPCs were evaluated by flow cytometry as CD34+/KDR+ cells. Capillary density was evaluated by videomicroscopy, before and after venous congestion, in the dorsum of the 4th finger. RESULTS:Patients treated with liraglutide (6 males 1 female, age 54 ± 12 years) showed a decrease in body mass index and blood pressure during treatment, while patients treated with exenatide (3 males 1 female, age 57 ± 6 years) did not show any relevant change. EPCs were significantly increased after treatment with exenatide, but not after treatment with liraglutide. Capillary density was slightly increased only after 4 weeks of treatment with exenatide, however the increase was no longer present at the final evaluation. CONCLUSIONS: Treatment with exenatide, but not with liraglutide, was able to increase the number of circulating EPCs, possibly through an antioxidative/antiinflammatory effect.
Authors: Bernard I Levy; Ernesto L Schiffrin; Jean-Jacques Mourad; Denis Agostini; Eric Vicaut; Michel E Safar; Harry A J Struijker-Boudier Journal: Circulation Date: 2008-08-26 Impact factor: 29.690
Authors: Cindy Jm Loomans; Rien van Haperen; Jacques M Duijs; Caroline Verseyden; Rini de Crom; Pieter Jm Leenen; Hemmo A Drexhage; Hetty C de Boer; Eelco Jp de Koning; Ton J Rabelink; Frank Jt Staal; Anton Jan van Zonneveld Journal: Mol Med Date: 2009-03-11 Impact factor: 6.354
Authors: Mark M Smits; Marcel H A Muskiet; Lennart Tonneijck; Mark H H Kramer; Michaela Diamant; Daniël H van Raalte; Erik H Serné Journal: Arterioscler Thromb Vasc Biol Date: 2015-04-23 Impact factor: 8.311
Authors: Hisko Oeseburg; Rudolf A de Boer; Hendrik Buikema; Pim van der Harst; Wiek H van Gilst; Herman H W Silljé Journal: Arterioscler Thromb Vasc Biol Date: 2010-05-06 Impact factor: 8.311
Authors: Juraj Koska; Michelle Sands; Camelia Burciu; Karen M D'Souza; Kalyani Raravikar; James Liu; Seth Truran; Daniel A Franco; Eric A Schwartz; Dawn C Schwenke; David D'Alessio; Raymond Q Migrino; Peter D Reaven Journal: Diabetes Date: 2015-02-26 Impact factor: 9.461